2026 Biopharma M&A Trends: Big Pharma’s $130 Billion H1 Deal Spree Nearly Tops All of 2025
Biopharma M&A in 2026 is estimated at $130B across 42 deals, nearly matching 2025’s $133B, according to IQVIA. Average deal size rose to $3.1B. The article cites patent expirations as a driver and highlights deals including GSK-Nuvalent ($10.6B), Merck-Terns ($6.7B), AbbVie-Apogee ($10.9B), Curium-Lantheus (up to $8B), Eli Lilly-Centessa ($7.8B), and Sun Pharma-Organon ($11.75B).
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the set of named deals with concrete economics (deal values, per-share terms, tender offers, CVRs) and specific regulatory or closing timelines that can affect deal probability and near-term sentiment.
Market read
A high-level M&A trend story, but it includes multiple named, deal-specific catalysts with hard terms and timelines that can move the involved issuers’ trading and M&A spreads.
What to watch
Execution risk is underweighted: FDA review timelines, contingent-payment triggers, and integration complexity can dominate returns versus the headline deal values.
Background
The piece frames 2026 biopharma M&A as driven by Loss of Exclusivity on major blockbusters and highlights several large transactions across oncology, immunology, radiopharma, neuroscience, and biosimilars.
Ticker impact
GSK announced a $10.6B acquisition of Nuvalent, including FDA-review lung-cancer drugs with September and November 2026 decision dates.
Likely supportive for sentiment while deal execution and FDA timelines remain key swing factors.
The article provides concrete deal size, tender offer price, and specific regulatory decision windows, which can drive trading around M&A probability and timeline risk.
AbbVie agreed to a $10.9B buyout of Apogee Therapeutics for zumilokibart, expanding IL-13 atopic dermatitis and asthma exposure.
Supportive for deal-driven sentiment, with upside capped by regulatory and clinical outcome uncertainty.
The article includes deal value, target indication, and competitive framing, but does not provide new clinical readouts beyond FDA review context.
Merck’s $6.7B Terns acquisition is positioned as pipeline replacement ahead of the 2028 Keytruda patent expiration.
Potentially positive, but likely to trade with broader M&A sentiment and any subsequent regulatory or trial updates.
The article provides the specific patent-expiration year and ties it to the acquired asset, which is actionable for forward risk modeling.
Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8B, adding orexin receptor 2 agonists including cleminorexton for narcolepsy.
Generally supportive, with follow-through dependent on clinical development and deal closing.
The text includes deal size, contingent payments, and the lead drug’s indication, giving traders concrete inputs for scenario analysis.
Market effects
Reinforces a sector-wide shift toward late-stage, de-risked assets and away from speculative early pipelines due to the patent cliff.
Cross-border dealmaking signals continued global capital allocation across US and international pharma assets.
If sustained, the reported pace implies a multi-quarter global M&A bid for oncology, immunology, CNS, and radiopharmaceutical platforms.
Counterpoint
The article may overstate “systemic” urgency; deal pace can slow if financing conditions tighten or if regulatory outcomes disappoint, making the forecast path less reliable.
Key entities
- data_providerIQVIA
Cited for mid-year transaction tracking and full-year deal-value forecast range.
- consulting_firmPwC
Cited for midyear outlook on continued demand for strategically important assets.
- analystRajesh Kumar
HSBC life sciences equity research head quoted on the patent-cliff-driven acquisition behavior.
